Dezhong Liao

Prof. Dezhong Liao

Guizhou Medical University, Guiyang, Guizhou 550004, China
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMing-Yang Li
Ming-Yang Li
LFLin-Ni Fan
Lin-Ni Fan
DHDong-Hui Han
Dong-Hui Han
ZYZhou Yu
Zhou Yu
JMJing Ma
Jing Ma
ZWZhe Wang
Zhe Wang
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancers and is highly resistant to current treatments. ESCC harbors a subpopulation of cells exhibiting cancer stem-like cell (CSC) properties that contribute to therapeutic resistance including radioresistance, but the molecular mechanisms in ESCC CSCs are currently unknown. Here, we report that ribosomal S6 protein kinase 4 (RSK4) plays a pivotal role in promoting CSC properties and radioresistance in ESCC. RSK4 was highly expressed in ESCC CSCs and associated with radioresistance and poor survival in patients with ESCC. RSK4 was found to be a direct downstream transcriptional target of ΔNp63α, the main p63 isoform, which is frequently amplified in ESCC. RSK4 activated the β-catenin signaling pathway through direct phosphorylation of GSK-3β at Ser9. Pharmacologic inhibition of RSK4 effectively reduced CSC properties and improved radiosensitivity in both nude mouse and patient-derived xenograft models. Collectively, our results strongly suggest that the ΔNp63α/RSK4/GSK-3β axis plays a key role in driving CSC properties and radioresistance in ESCC, indicating that RSK4 is a promising therapeutic target for ESCC treatment.

1 February 2018 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
XLxingde Liu
xingde Liu
WYWenxiu Yang
Wenxiu Yang
ZGZhizhong Guan
Zhizhong Guan
WYWenfeng Yu
Wenfeng Yu
BFBin Fan
Bin Fan
DLDezhong Liao
Dezhong Liao
There have been enough cell death modes delineated in the biomedical literature to befuddle all cell death researchers. Mulling over cell death from the viewpoints of the host tissue or organ and of the host animal, we construe that there should be only two physiological cell death modes, i.e. apoptosis and senescent death (SD), as well as two pathological modes, i.e. necrosis and stress-induced cell death (SICD). Other death modes described in the literature are ad-hoc variants or coalescences of some of these four basic ones in different physiological or pathological situations. SD, SICD and necrosis kill useful cells and will thus trigger regeneration, wound healing and probably also scar formation. SICD and necrosis will likely instigate inflammation as well. Apoptosis occurs as a mechanism to purge no-longer useful cells from a tissue via phagocytosis by cells with phagocytic ability that are collectively tagged by us as scavengers, including macrophages; therefore apoptosis is not followed by regeneration and inflammation. The answer for the question of “who dies” clearly differentiates apoptosis from SD, SICD and necrosis, despite other similarities and disparities among the four demise modes. Apoptosis cannot occur in cell lines in vitro, because cell lines are immortalized by reprogramming the death program of the parental cells, because in culture there lack scavengers and complex communications among different cell types, and because culture condition is a stress to the cells. Several issues of cell death that remain enigmatic to us are also described for peers to deliberate and debate.

16 January 2018 in Genes
Verified
Journal Article
Open access
PDF file
YHYan He
Yan He
CYChengfu Yuan
Chengfu Yuan
LCLichan Chen
Lichan Chen
MLMingjuan Lei
Mingjuan Lei
LZLucas Zellmer
Lucas Zellmer
DLDezhong Liao
Dezhong Liao
Tens of thousands of chimeric RNAs, i.e., RNAs with sequences of two genes, have been identified in human cells. Most of them are formed by two neighboring genes on the same chromosome and are considered to be derived via transcriptional readthrough, but a true readthrough event still awaits more evidence and trans-splicing that joins two transcripts together remains as a possible mechanism. We regard those genomic loci that are transcriptionally read through as unannotated genes, because their transcriptional and posttranscriptional regulations are the same as those of already-annotated genes, including fusion genes formed due to genetic alterations. Therefore, readthrough RNAs and fusion-gene-derived RNAs are not chimeras. Only those two-gene RNAs formed at the RNA level, likely via trans-splicing, without corresponding genes as genomic parents, should be regarded as authentic chimeric RNAs. However, since in human cells, procedural and mechanistic details of trans-splicing have never been disclosed, we doubt the existence of trans-splicing. Therefore, there are probably no authentic chimeras in humans, after readthrough and fusion-gene derived RNAs are all put back into the group of ordinary RNAs. Therefore, it should be further determined whether in human cells all two-neighboring-gene RNAs are derived from transcriptional readthrough and whether trans-splicing truly exists.

1 April 2016 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YLYuying Liao
Yuying Liao
GMGuodong Mo
Guodong Mo
JSJunli Sun
Junli Sun
FWFengying Wei
Fengying Wei
DLDezhong Liao
Dezhong Liao

1 January 2016 in Journal of Carcinogenesis
Verified
Journal Article
Open access
PDF file
YJYuping Jia
Yuping Jia
NXNingzhi Xu
Ningzhi Xu
DLDezhong Liao
Dezhong Liao
LCLichan Chen
Lichan Chen
QJQingwen Jia
Qingwen Jia
XDXixi Dou
Xixi Dou
"Gene amplification causes overexpression" is a longstanding and well-accepted concept in cancer genetics. However, raking the whole literature, we find only statistical analyses showing a positive correlation between gene copy number and expression level, but do not find convincing experimental corroboration for this notion, for most of the amplified oncogenes in cancers. Since an association does not need to be an actual causal relation, in our opinion, this widespread notion still remains a reasonable but unproven assumption awaiting experimental verification.

4 December 2012 in Prostate Cancer
Verified
Journal Article
Open access
PDF file
MBMelissa J. L. Bonorden
Melissa J. L. Bonorden
MGMichael E. Grossmann
Michael E. Grossmann
SESarah A. Ewing
Sarah A. Ewing
OROlga P. Rogozina
Olga P. Rogozina
ARAmitabha Ray
Amitabha Ray
MCMargot Cleary
Margot Cleary
To clarify effects of diet and body weight on prostate cancer development, three studies were undertaken using the TRAMP mouse model of this disease. In the first experiment, obesity was induced by injection of gold thioglucose (GTG). Age of prostate tumor detection (~33 wk) and death (~43 wk) was not significantly different among the groups. In the second study, TRAMP-C2 cells were injected into syngeneic C57BL6 mice and tumor progression was evaluated in mice fed either high-fat or low-fat diets. The high fat fed mice had larger tumors than did the low-fat fed mice. In the third study, tumor development was followed in TRAMP mice fed a high fat diet from 6 weeks of age. There were no significant effects of body weight status or diet on tumor development among the groups. When the tumors were examined for the neuroendocrine marker synaptophysin, there was no correlation with either body weight or diet. However, there was a significant correlation of the expression of synaptophysin with earlier age to tumor detection and death. In summary, TRAMP-C2 cells grew faster when the mice were fed a high-fat diet. Further synaptophysin may be a marker of poor prognosis independent of weight and diet.